<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691220</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-0061</org_study_id>
    <secondary_id>U01DK119200</secondary_id>
    <nct_id>NCT03691220</nct_id>
  </id_info>
  <brief_title>Improving Medication Adherence in Adolescents Who Had a Liver Transplant</brief_title>
  <acronym>iMALT</acronym>
  <official_title>Improving Medication Adherence in Adolescents Who Had a Liver Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory-Children's Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's aim is to test a tailored telemetric intervention to reduce rejection incidence
      by improving medication adherence in a group of adolescent liver transplant recipients
      identified as nonadherent by a marker (the Medication Level Variability Index, MLVI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, randomized controlled trial. The study will be conducted
      in 11 transplant centers in the United States and Canada. Estimated final sample size of 140.
      Pediatric adolescent and young adult (age at enrollment ≥12 and &lt; 18) transplant recipients
      will be eligible for participation in the study. Eligible participants will be randomly
      assigned to intervention or control group. An interim analysis to evaluate efficacy will be
      performed. Missing data will not be imputed for secondary analyses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study participants will be randomized to receive the telemetric intervention or standard of care.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Study pathologists will perform masked reading of for-cause biopsy slides.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Rejection</measure>
    <time_frame>2 Years</time_frame>
    <description>The incidence of biopsy-proven acute cellular rejection (number of patients experiencing at least one episode of rejection) at any time during the 2 years of follow up.Biopsy-confirmed late acute rejection, as determined by the majority of 3 masked readings of liver biopsy images by 3 pathologists that are not from the clinical site at which the patient is treated. Patients with incomplete follow-up (for example due to death, re-transplant, listing for re-transplantation), will be assumed to have experienced a rejection for the purpose of the primary analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Standard Deviation of A Series Of Tacrolimus Levels (MLVI)</measure>
    <time_frame>2 Years</time_frame>
    <description>MLVI = Standard Deviation Of Tacrolimus Blood Levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Locally Determined Biopsy Proven Rejection</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate Of Locally Determined Biopsy Proven Rejection</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Centrally Determined Biopsy Proven Rejection</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Rejection From Enrollment</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Death</measure>
    <time_frame>2 Years</time_frame>
    <description>Number of deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Re-Listing For Transplantation</measure>
    <time_frame>2 Years</time_frame>
    <description>Number of participants listing for retransplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean ALT</measure>
    <time_frame>2 Years</time_frame>
    <description>Mean number of achieving above threshold ALT &gt; 150 Alanine Aminotransferase (ALT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean maximal ALT</measure>
    <time_frame>2 Years</time_frame>
    <description>mean/maximal and ALT (defined as in MALT as the mean of all levels recorded during the study period and the maximal level recorded during the study period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean gGT</measure>
    <time_frame>2 Years</time_frame>
    <description>Mean number of achieving above threshold GGT &gt; 150 Gamma Glutamyl Transferase (gGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean maximal gGT</measure>
    <time_frame>2 Years</time_frame>
    <description>mean/maximal gGT (defined as in MALT as the mean of all levels recorded during the study period and the maximal level recorded during the study period)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Transplant</condition>
  <arm_group>
    <arm_group_label>Telemetric Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescent with MLVI&gt;2 to receive the telemetric intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Adolescent with MLVI&gt;2 to receive standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telemetric Intervention</intervention_name>
    <description>Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.</description>
    <arm_group_label>Telemetric Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is ≥ 12 and &lt; 20 years of age at enrollment.

          -  ≥2.5 years after last liver transplantation.

          -  Guardian's consent, adolescent assent at enrollment.

          -  The patient is prescribed tacrolimus.

          -  The patient's MLVI (SD of tacrolimus) was &gt; 2 when calculated by the site for a period
             of 2 years prior to the review date

        Exclusion Criteria:

          -  The patient has had transplant of an organ other than liver.

          -  The patient is currently listed for any organ transplantation.

          -  The patient is expected to transition to another service (e.g., adult clinic, another

          -  hospital) during the two years of the study.

          -  Pregnant patients.

          -  A temporary exclusion: the patient is not medically stable or was hospitalized for &gt;48
             consecutive hours in the past three months.

          -  Site PI, study PI, or Medical Monitor determines that the patient should not be a
             candidate for the intervention due to factors that are not covered in the above
             criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eyal Shemesh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kinga Picerno, M.S.Ed.</last_name>
    <phone>212-241-2842</phone>
    <email>Kinga.Picerno@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Annunziato, Ph.D.</last_name>
    <phone>212-659-8776</phone>
    <email>Rachel.Annunziato@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mattel Children's Hospital UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Feist, RN</last_name>
      <phone>310-825-4349</phone>
      <email>SFeist@Mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Robert S Venick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benioff Children's Hospital UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Zerofsky</last_name>
      <phone>415-502-6346</phone>
      <email>Melissa.Zerofsky@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Perito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Cleeton, MPH, CCRP</last_name>
      <phone>404-727-5383</phone>
      <email>rcleeto@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Rene Romero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Neighbors, MPH</last_name>
      <phone>312-227-4557</phone>
      <email>KNeighbors@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Estella Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C.S.Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally J Eder, BA</last_name>
      <phone>734-615-4271</phone>
      <email>Saleder@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Emily M Fredericks, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinga Picerno, M.S. Ed.</last_name>
      <phone>212-241-2842</phone>
      <email>Kinga.Picerno@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Annunziato, Ph.D</last_name>
      <phone>212-659-8776</phone>
      <email>Rachel.Annunziato@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eyal Shemesh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Bayona</last_name>
      <phone>212-305-3839</phone>
    </contact>
    <investigator>
      <last_name>Steven J Lobritto, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Rand, MD</last_name>
      <phone>215-590-7801</phone>
      <email>Rand@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Rand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Rzempoluch</last_name>
      <phone>412-692-5201</phone>
      <email>alexis.rzempoluch@chp.edu</email>
    </contact>
    <investigator>
      <last_name>George Mazariegos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Economides</last_name>
      <phone>832-824-0411</phone>
      <email>jmeconom@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Tamir Miloh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Hospital For Sick Children Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blossom Dharmaraj</last_name>
      <phone>416-813-7654</phone>
      <email>blossom.dharmaraj@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Vicky Ng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://imalt.org/</url>
    <description>Official Website of The iMALT Study</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Eyal Shemesh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Intervention</keyword>
  <keyword>Adherence</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

